Atopic dermatitis (also known as eczema) is one of the commonly seen skin conditions. It makes the sufferer’s skin itchy and red. Children are the common sufferers of eczema but people of any age group can become a sufferer. In short, atopic dermatitis is a chronic or long-term condition, and it may aggravate from time to time. Moreover, eczema can attack a person with hay fever or asthma.
Although no straightforward treatment is available for atopic dermatitis, treatments can be given for alleviating the symptoms. Furthermore, appropriate self-care is also critical in this regard. Thus, the eczema sufferer can prevent the deterioration of the condition. For instance, patients should stay away from harsh soaps and should moisturize their skin daily. The application of medicated ointments or creams also helps to relieve the symptoms.
Atopic Dermatitis: Latest Industry Trends
- In 2016, the global drug market size for atomic dermatitis was estimated at USD 4.1 billion. However, it is predicted that the market would grow at a 6.6% of CAGR (Compound Annual Growth Rate) throughout the forecast period.
- Note that atopic dermatitis or AD is the most commonly seen eczema in patients. A vast percentage of people worldwide get affected by atopic dermatitis. Mostly, infants and kids get affected by atopic dermatitis, and the outbreak lessens with age. The high percentage of AD patients acts as the accelerator of the atopic dermatitis drugs market.
- The actual cause of AD is unknown until today. Nonetheless, it is assumed that the amalgamation of genetic and environmental factors is responsible for this health condition.
- Around 60.0% of patients, suffering from atopic dermatitis, develop typical symptoms in the initial year itself. However, approximately 90.0% of patients develop the signs of AD by their fifth birthday (called “atopic march”).
- Rarely people aged 30+ develop atopic dermatitis. Harsh environmental factors contribute to the symptoms of atopic dermatitis.
More Information
- The atopic dermatitis drugs market is predicted to grow at a modest speed during the forecast period. Various factors are working as accelerators to grow the AD drug market. It includes the launching of more small molecules and biologics, high-priced drugs, and growing atopic dermatitis cases. The first three factors are substituting the first-line as well as second-line therapeutics.
- The awareness about the advanced treatments of atopic dermatitis has increased. It has further helped to grow the market over the last couple of years.
- The market is also growing due to several policies taken for introducing budget-friendly treatment and beneficial reimbursements. Moreover, the popularity of targeted atopic dermatitis therapies like Dupixent and Eucrisa has also increased. It is also accelerating the market growth.
What about the Drug Class of Atopic Dermatitis?
The atopic dermatitis market is divided into many segments based on the drug class. Some of the segments include calcineurin inhibitors, biologics, corticosteroids, PDE4 inhibitors, etc.
Corticosteroids have been the key class of drug for atopic dermatitis treatment. Since corticosteroids are the first-line AD therapy, it is expected to keep a major share in the market by 2022. Corticosteroids maintained around 45.0% share in the atopic dermatitis drug market in the year 2016.
